Table 1.
Baseline and follow-up characteristics (n=3096)
| At renal biopsy | Values at renal biopsy |
| Cohorts: Oxford, the VALIGA Study, Japan, China, na | 234, 1145, 700, 1017 |
| Women, % | 42 |
| Ethnicity: white, Asian, other, % | 41, 58, 1 |
| Age, yr | 35±14 |
| eGFR, ml/min per 1.73 m2 | 78±29 |
| MAP, mmHg | 97±15 |
| Proteinuria, g/d | 1.2 (0.7–2.3) |
| Pathology findings | % of total biopsies |
| M1 | 33 |
| E1 | 20 |
| S1 | 77 |
| T0, T1, T2 | 75, 20, 5 |
| Crescents (cellular or fibrocellular) | 36 |
| Follow-up parameters | Values during follow-up |
| Length of follow-up, yr | 4.7 (2.9–7.0) |
| Any immunosuppression, % | 37 |
| RASB, % | 74 |
| MAP, mmHgb | 95±10 |
| Proteinuria, g/db | 0.8 (0.4–1.4) |
| Rate of renal function decline, ml/min per 1.73 m2 per yr | −1.9±6.3 |
| ESRD, % | 11 |
| Combined event, % | 13 |
Values are expressed as means±SD, medians (interquartile ranges), or percentages.
a
Excluding 44 individuals with no information on crescents or immunosuppressive therapy during follow-up.
b
Time averaged.